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Summary The synthetic polypeptide, poly-L-aspartic acid (PAA, mol. wt =20,000) has been used as a
macromolecular carrier for doxorubicin. The drug may be released in vivo through hydrolysis of the ester
linkage formed between the carboxyl groups of the polymer and the drug side chain. PAA has been found to
be a suitable carrier since it is a soluble, biodegradable, multivalent and nontoxic polymer. The toxicity and
the therapeutic efficacy of free and polymer-linked doxorubicin have been evaluated in normal and tumour-
bearing mice, using a variety of experimental tumour systems. In studies on single and multiple drug
administration, the results indicated that the polymeric derivative of doxorubicin had approximately 3-fold
lower toxicity than did free drug. In addition, the severity of specific toxic effects, including cardio- and
vesicant toxicity, were appreciably reduced following conjugation to PAA. The doxorubicin-PAA conjugate
gave similar or rather greater therapeutic effects than free drug at less toxic doses. This effect, more evident in
the highly sensitive tumours, suggests an improvement of the therapeutic index of the polymer-linked drug.
In an attempt to improve tumour drug uptake and,
therefore, the selectivity of antitumour agents,
many carrier systems have been tested. Means of
drug delivery include target-specific biological
carriers (Ghose et al., 1983) as well as other non-
specific microparticulate, macromolecular and
synthetic carriers (Gregoriadis, 1981; Gros et al.,
1981). Macromolecular drug carrier systems have
been extensively developed in an attempt to modify
the pharmacokinetic behaviour of antitumour drugs
(Kaye, 1981).
Although preferential delivery of the drug to
tumour cells remains to be documented, linkage of
cytotoxic agents to suitable macromolecules has
been found to improve therapeutic efficacy (Arnon
& Hurwitz, 1983). In some cases, the therapeutic
advantage of the macromolecular derivative is
related to reduction of systemic drug toxicity, thus
allowing the administration of higher doses (Levi-
Schaffer et al., 1982).
Recently, we have reported that daunorubicin
covalently linked to poly-L-aspartic acid (PAA)
reduce the toxicity of the anthracycline, whereas it
maintained or improved the antitumour efficacy
(Zunino et al., 1982, 1984). Doxorubicin may be
released in vivo through hydrolysis of the ester
linkage formed between the carboxyl group of the
polymer and drug side chain. These results have
generated considerable interest, since the polymeric
drug form might be ofpotential clinical relevance.
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Thus, the present studies were initiated to further
document the preclinical efficacy of doxorubicin
conjugated with PAA. Polymer-bound doxorubicin
was compared to free drug with respect to some
toxic effects. In addition, this paper describes
detailed in vivo evaluation of free and PAA-bound
doxorubicin against experimental tumour systems
with particular reference to solid tumours.
Materials and methods
Drugs
Daunorubicin, doxorubicin and 14-bromo-dauno-
rubicin were supplied by Farmitalia Carlo Erba
(Milan, Italy) as hydrochlorides. Drug solutions
were freshly prepared immediately before use. PAA
(mol. wt 20,000) was obtained from Sigma
Chemical Co. (St Louis, Mo., USA). Doxorubicin-
PAA conjugate (poly-L-aspartic acid doxorubicinyl
ester; previously referred to as daunorubicin-PAA
conjugate since a daunorubicin derivative was used
in the conjugation procedure) was prepared
essentially according to the previously described
procedure (Zunino et al., 1982, 1984). Attachment
of drug to PAA was achieved by nucleophilic
substitution reaction of 14-bromo-daunorubicin.
Thus, an ester linkage was formed between the
drug side chain and carboxyl groups of the
polyamino acid. The various preparations of doxo-
rubicin-PAA conjugate used in this study contained
18-70mol drug mol-1 ofPAA.
The concentration of anthracycline in the
polymeric derivative was determined by absorbance
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at 495 nm. The conjugate was stable in aqueous
solution for at least 1 month as checked by thin-
layer chromatography, using a mixture of chloro-
form:methanol:acetic acid (80:20:4) as a solvent.
In all experiments, the dose of the do:;orubicin-
PAA conjugate was expressed as drug content in
the polymeric derivative.
Animals
The mice and rats of both sexes employed
throughout the experiments were obtained from
Charles River Laboratories (Calco, Como, Italy).
Mice weighed between 17 and 22g.
Evaluation oftoxicity
Drug-induced mortality was assessed in healthy
C3H/He mice treated i.v. with single or multiple
doses of doxorubicin, and doxorubicin-PAA and
followed for 110 days, since mice that did not die
soon after treatment died approximately 2-3
months later. At necropsy, mice showed spleen and
liver size reduction and haemorrhagic degeneration
of intestinal mucosa.
In tumour-bearing mice, deaths that occurred in
treated animals before the first death of an
untreated control were attributed to drug toxicity.
Normal healthy mice were treated i.v. according to
the same schedules used for the solid-tumour-
bearing mice, and recorded for 120 days.
Cardiotoxicity was assessed in healthy female
C3H/He mice treated according to the same
schedule used for treatment of mammary-
carcinoma-bearing mice (q7d x 4i.v.). Forty and 90
days after the last treatment, mice were killed and
hearts were removed and fixed in paraformaldehyde
(4% in 0.1M phosphate buffer at pH 7.3). Histo-
logical examination of semi-thin sections was carried
out as previously described (Bertazzoli et al., 1979).
Myocardial lesions were graded according to:
(severity degree) x(extension degree). The histo-
logical examinations were blind.
The vesicant activity was assessed in Sprague-
Dawley rats weighing about 250mg. Rats were
injected i.d. in both flanks with 1 ml of a solution
containing different drug concentrations in distilled
water. The healing scar was measured on day 12 on
its largest dimension and was scored as follows:
I + = _Smm; 2+ =6-lOmm; 3+ = >lOmm.
Scores were added and expressed as a response
fraction (RF) of the possible total cumulation score
of 3+ for each rat (Jenkins & Corden, 1983).
Tumours
The macrophage tumour J774 was serially main-
tained in ascitic form in female BALB/c mice. For
chemotherapy experiments, 106 cell/mouse were
injected i.p. in female BALB/c or CDF1
(BALB/c x DBA/2) mice (Tarnowski et al., 1979).
Lewis lung carcinoma was serially maintained
according to Geran et al. (1972). The experiments
were carried out in BDF1 (C57BL x DBA/2) mice,
inoculated i.m. with 5 x 105 cells/mouse.
M5076/73A (M5), a murine reticulum cell
sarcoma, was transplanted i.m. in the right hind leg
of female C57BL mice by injection of 5 x 105
cells/mouse, for serial passages and chemotherapy
experiments (Talmadge et al., 1981). In the ascitic
form, 2 x 106 cells/mouse were implanted i.p. in
female BDF1 mice.
Mammary adenocarcinoma, spontaneously arisen
in a retired female C3H/He breeder, was
transplanted in the left axillary region in female
C3H/He mice. The chemotherapy experiment was
carried out on second generation transplant in
female C3H/He mice injected with 2 x 107
cells/mouse (Di Marco et al., 1972).
Evaluation ofantitumour activity
Unless otherwise indicated, for antitumour activity
experiments 10mice/group were used. The effect on
survival is expressed as percentage ILS (increase
in life span) calculated as follows: ILS=
[(T/C)-1] x 100, where T/C is the median survival
time (MST) of dying mice only in the treated
group (T) divided by the MST of the untreated
control group (C). Long-term (at least 90 days)
survivors (LTS) were considered cured and were
noted separately.
In the mice injected with solid growing tumours,
tumour growth was assessed by weekly caliper
measurement of the two tumour diameters and
tumour weight was obtained according to Geran et
al. (1972). In experiments carried out against early
tumour, the anti-tumour activity was established by
the percentage of tumour growth inhibition of the
treated mice as compared to the controls at the day
indicated in each experiment.
In the experiments designed to evaluate anti-
tumour activity against advanced tumours, tumour
weight in individual mice was determined at the
beginning of treatment, and tumour growth was
then evaluated for individual mice as the percentage
change in tumour weight 1 week after the last
treatment. The data reported as relative tumour
weight represent the average of individual tumour
weight change for each group.
Student's t test was used for statistical
comparisons.
Results
Toxicity in non-tumour-bearing mice
Table I shows that linkage of the anthracycline toPAA AS A DOXORUBICIN CARRIER 843
Table I Lethal toxicity of free and poly-L-aspartic acid (PAA)-
bound doxorubicin (DX)
Mouse No. of Survival
strain Drug Dosea treatments Deaths range (d)
C3H/He DX 13 1 0/8
males 16.9 1 4/8 16-52
22 1 8/8 5-68
DX-PAA 22 1 0/8
28.5 1 0/8
37 1 2/8 22-45
C3H/He DX 6 4 3/15 88-90
females 7.5 4 9/14 15-90
DX-PAA 15 4 0/5
18 4 4/15 30-87
21.5 4 10/10 22-105
C57BL DX 6 3 3/10 5-11
females 7.5 3 9/10 5-65
9 3 10/10 11-81
DX-PAA 14.4 3 0/10
18 3 0/10
22.5 3 1/10 22
amgkg-linjection-1, i.v. In the case of the DX-PAA conjugate,
the dose refers to the actual amount of drug in the conjugate.
PAA markedly reduced drug toxicity in different
mice strains after i.v. administration of single or
multiple weekly doses. After a single i.v. injection
of the drugs to male C3H/He mice, the LD2s
values were -15 and 37mgkg-' for doxorubicin
and doxorubicin-PAA, respectively. Thus, the ratio
between these equitoxic doses of doxorubicin-PAA
and free doxorubicin was 2.5.
The chronic lethal toxicity of the drug on the
same strain caused by 4 weekly i.v. injections could
be further reduced when given in the polymeric
form; thus, the ratio between equitoxic doses of
doxorubicin-PAA (18mgkg-1) and doxorubicin
(6mgkg- 1) was -3 in this experiment. Moreover,
in C57BL mice, doxorubicin-PAA conjugate seemed
definitely better tolerated than free doxorubicin
using a multiple treatment schedule (q7d x 3,i.v.); in
this strain, the ratio between equitoxic doses was
more than 3 (doxorubicin-PAA 22.5mgkg' vs.
doxorubicin <6 mgkg -1).
Data from the cardiotoxic test in C3H female
mice (Table II) showed that the linkage of the
anthracycline to PAA also reduced this organ-
specific damage. The dose of doxorubicin-PAA
must be increased 3-fold relative to free
doxorubicin in order to produce a comparable
effect in the heart. This parallels the effect on
mortality.
The ulcerogenic potential of doxorubicin and its
polymeric derivative was assessed in Sprague-
Dawley rats (Table III). The vesicant action of
Table II Cardiotoxicity in C3H/He mice
Lesion gradec at dayd
40e 90
Druga Doseb LA' Vg LA V
DX 6 1.2 1.9 0.7 1.5
7.5 2.3 3.3 1.7 5.0
DX-PAA 15 0.7 0.8 0.3 0.6
18 0.6 1.6 0.4 1.2
21.5 1.3 3.2
aDX, doxorubicin; PAA, poly-L-aspartic acid;
bmgkg-'injection-', q7q x 4 i.v. In the conjugate, the
dose is expressed as dose of drug component; cGiven by
the product of (severity degree) x(extension degree);
dCalculated from the last treatment; eData collected from
two experiments (5 mice/group). One experiment was
carried out in parallel with anti-tumour activity assay
(Table VIII); 'Left atrium; gVentricles.
2.4mg of doxorubicin-PAA was lower than that
induced by 0.6mg of doxorubicin. The doxorubicin-
PAA conjugate at lower dose (1 mg) did not show
appreciable vesicant activity.
Anti-tumoural activity studies
Since in the treatment of drug-sensitive tumours,
the antitumour effects of the doxorubicin-PAA844 G. PRATESI et al.
Table III Vesicant activity of doxorubicin
(DX) and the DX-poly-L-aspartic acid (PAA)
conjugate
Amount No. of
Drug (mg) rats RFa
DX 1 6 0.83
0.6 8 0.70
DX-PAA 2.4 6 0.50
1 2 0.00
aResponse fraction.
methods for details.
See Materials and
conjugate were found to be dose-dependent
(Zunino et al., 1982, 1984) and, as already observed
for other antitumour drugs, optimal treatment was
at the maximum tolerated doses, in antitumour
activity experiments the dose levels were usually
selected in the range of the highest non-toxic doses
(.LD1O). The relative effectiveness of doxorubicin,
in the survival time than did doxorubicin. However,
the difference was not statistically significant.
Table VI shows the effect of doxorubicin and
doxorubicin-PAA on i.m. implanted M5 tumour in
female C57BL mice using a multiple treatment
schedule (q7d x 3, i.v.) starting on day 1 after
tumour implant. Doxorubicin-PAA gave a complete
inhibition of tumour growth at the LD1O (i.e.,
22.5mgkg-1) and even at a lower dose. However,
doxorubicin produced complete inhibition only at
toxic doses (7.5 and 9mgkg-1). Both the
compounds slightly increased the survival time of
tumour-bearing mice.
The effects of i.v. treatments (q3d x 4, beginning
on day 1 after tumour implant) with doxorubicin
and polymeric derivative on Lewis lung carcinoma
are shown in Table VII. Doxorubicin was active in
inhibiting tumour growth at 5 mgkg-1. Its activity
was not statistically different from that produced
by doxorubicin-PAA at 18mgkg-1. By 120 days, 9
of 10 of the doxorubicin-(7.5 mgkg-1)-treated mice
survived, whereas in another experiment 7 of 10
Table IV Anti-tumoural activity against i.p. J774 tumour
ILS Toxic
Drugsa Doseb (Y)c deathsd LTSC
DX 6.6 123 (68,178) 1/18 3/18
10 94 (76,112) 0/18 5/18
DR 3.3 39 (39,40) 1/18 0/18
5 -15 (-29,0) 8/18 0/18
DX-PAA 30-32 102 (113,91) 2/18 2/18
40-45 -21 (-40, -2) 10/18 3/18
aDX, doxorubicin; DR, daunorubicin; DX-PAA, doxorubicin-poly-
L-aspartic acid conjugate; bmgkg-1, treatment i.p. on day 1. Dose
refers to actual amount of drug in the conjugate; cln parenthesis, the
values of each experiment. MST of the control mice was 19 and 23.5
days in the two experiments. Nine mice/group were used in each
experiment; dEvaluated in tumour-bearing mice; eEvaluated 90 days
after inoculation of tumour cells.
daunorubicin and doxorubicin-PAA in the
treatment of early ascitic J774 tumour is presented
in Table IV. When administered as a single dose
i.p. one day after cell inoculation, daunorubicin
slightly increased the survival time at the optimal
dose of 3.3 mgkg-1. Doxorubicin and doxorubicin-
PAA, at their respective optimal doses (6.6 and
32mgkg-1), markedly increased the survival time
of the tumour-bearing mice, producing also long-
term survivors. Although the activity was
comparable for the two drugs, doxorubicin-PAA
gave more reproducible effects.
After a single i.p. treatment of M5 ascitic tumour
(Table V), doxorubicin-PAA gave a higher increase
Table V Anti-tumour activity against M5 ascitic
tumour
ILS Toxic
Druge Doseb (Y)C deaths'
DX 6.6 63 1/10
10.0 54 1/10
DX-PAA 26.0 90 0/10
32.0 107 0/10
aDX, doxorubicin; DX-PAA, doxorubicin-poly-L-
aspartic acid conjugate; bmgkg-', treatment i.p. on
day 1. Dose refers to actual amount of drug in the
conjugate; CMST of the control mice was 22 days;
dEvaluated in tumour-bearing mice.PAA AS A DOXORUBICIN CARRIER 845
Table VI Anti-tumour activity against M5 solid tumour
7iTmour weightc ILS(%)d
Toxice
Druga Doseb Exp. I Exp. 2 Exp. I Exp. 2 deaths
DX 6 140+200 (95) 270+400 (92) 21 15 3/10
7.5 0 (100) 38 9/10
9 0 (100) 32 10/10
DX-PAA 11.2 1520+300 (42) 17 0/10
17.2 790+360 (70) 0 (100) 20 18 0/10
22.5 0 (100) 39 1/10
aDX, doxorubicin; DX-PAA, doxorubicin-poly-L-aspartic acid conjugate; bmgkg- injection-1,
q7d x 3,i.v., starting from day 1. In the conjugate, dose refers to actual amount ofdrug; cMean±s.d.
measured on day 21 after tumour transplantation; in parenthesis, percentage inhibition. The average
tumour weight of control mice was 2610(±500)mg (experiment 1) and 3621 (±770)mg (experiment
2); dMST of control mice was 32.5 (experiment 1) and 31 days (experiment 2). Ten mice per group
were used; 'Evaluated at 120 days in healthy female C57BL mice.
Table VII Anti-tumour activity against Lewis lung carcinoma
Tumour Tumour growth ILS Toxic
Drug' Doseb weight (mg)c inhibition (%) (%)d deathse
DX 5 730+710 87 60 1/10
7.5 0 100 ND' ND
DX-PAA 12 2660+990 53 20 0/10
18 380+410 93 86 0/10
'DX, doxorubicin, DX-PAA, doxorubicin-poly-L-aspartic acid conjugate;
bmgkg- injection-1, q3dx4,i.v. starting from day 1. In the conjugate, the
dose is expressed as actual amount of drug; cMean+s.d. measured on day 21
after tumour transplantation. The average tumour weight of control mice was
5647(±2710)mg; dMST of control mice was 22.5 days; eIn tumour-bearing
mice; 'Not determined. See Results for details.
mice died from toxicity. Both the compounds had a
similar effect on survival time.
Table VIII compares the activity of doxorubicin
and doxorubicin-PAA in the treatment of advanced
mammary carcinoma (-.75mg) implanted in
C3H/He mice, with drug administration on the
q7d x 4 (i.v.) schedule. At equitoxic doses
(doxorubicin, 6mgkg-1 and doxorubicin-PAA,
18mgkg 1), the conjugate produced a somewhat
greater tumour inhibition (82%) than that
produced by free doxorubicin (63%), although the
difference was not statistically significant.
Moreover, doxorubicin-PAA produced a similar
inhibition (76%) at a non-toxic dose (15mgkg-1).
Both drugs were ineffective in increasing survival
time.
Discussion
The results presented in this study indicate that, in
comparison to free drug, administration of doxo-
rubicin covalently linked to the anionic polyamino
acid, PAA, resulted in reduced toxicity, after single
and after multiple administrations. Decreased
systemic toxicity paralleled reduction in severity of
specific toxic effects, including cardiotoxicity,
probably related to decreased heart uptake of the
drug (Mazzoni et al., in preparation). This obser-
vation is of particular interest, since potentially
irreversible cardiac damage is the major dose-
limiting toxicity for doxorubicin (Lenaz & Page,
1976). In particular, since in the same experiment
(using healthy and tumour-bearing CH3 mice) we
could compare cardiotoxic, lethal and anti-tumour
effects, a therapeutic improvement following linkage
of the anthracycline to the polymer could be
directly shown (Tables II and VIII). Indeed,
although equitoxic doses of free doxorubicin
(6mgkg-1) and doxorubicin-PAA (18mgkg-')
caused comparable heart lesions and had similar
effects on tumour growth, the doxorubicin-PAA
conjugate retained anti-tumour activity at a lower846 G. PRATESI et al.
Table VIII Anti-tumour activity against advanced C3H mammary carcinoma
Relative Tumour growth
tumour weight inhibition ILS Toxic
Drug' Doseb (%) C (O) (%)d deathse
DX 6 2751+1640 63 -7 3/15
7.5 668+ 490 91 12 9/14
DX-PAA 15 1810+ 905 76 -6 0/5
18 1326+ 865 82 8 4/15
21.5 ND' ND ND 10/10
"DX, doxorubicin; DX-PAA, doxorubicin-poly-L-aspartic acid conjugate;
bmgkg-1injection'- , q7d x 4,i.v., starting when tumour weight was - 75mg. In the
conjugate, the dose is expressed as dose of drug component; CMean+s.d. measured
on day 48 after tumour transplantation (1 week after the last treatment); the relative
tumour weight for control mice was 7411 (±3092)%; dMST of control mice was 74
days. Nine mice per group were used; eEvaluated at 120 days in healthy female
C3H/He mice; fND, not determined.
dose (15mgkg-1). This dose level was well
tolerated and definitely caused less cardiotoxic
damage.
In addition, the marked attenuation of dermal
toxicity of the drug in the polymeric derivative
might have obvious practical implications.
Reduction of local toxicity is also consistent with
the observation that high doses of the conjugate
were well tolerated after i.p. administration
(Zunino, 1982). Again, this might have clinical
relevance because of the therapeutic potential of
doxorubicin in the intraperitoneal chemotherapy of
abdominal neoplastic diseases (Myers & Collins,
1983).
The anti-tumour activity, evaluated in a number
of experimental models, indicated that doxorubicin
linked to the polyamino acid provided therapeutic
effects similar to those of free drug at less toxic
doses. In fact, as summarised in Table IX, the data
obtained in the treatment of three solid growing
tumours do show a trend toward an improved
therapeutic index of the drug following polymer
linkage, although a quantitative assessment of this
improvement is difficult to make due to the limited
number of doses used in these experiments. An
improvement in the therapeutic index resulting
from conjugation was more evident in the MS
model. Further studies aimed at other tumour
models and different schedules would therefore be
appropriate. Thus, although the covalent linkage of
the drug to polymer also resulted in a reduction in
drug potency, the therapeutic advantage, reflected
by a greater margin of safety, was generally
observed in a variety of experimental models
(Zunino et al., 1982, 1984).
Moreover, the results indicated that the
doxorubicin-PAA conjugate was also superior to
free drug against MS tumour, a reticulum cell
sarcoma (Talmadge et al., 1981). It remains
uncertain whether the increased therapeutic efficacy
Table IX Comparison of therapeutic ratios of free and PAA-bound
doxorubicin
Effective
Experimental model dose LDIO Therapeutic
(solid tumours) Druge (mgkg- )b (mgkg-') ratioc
M5 DX 6 < 6 <1
DX-PAA 17.2 22.5 1.3
Lewis lung DX 5 5 1
DX-PAA 18 > 18 >1
Advanced C3H DX 7.5 < 6 <0.8
Mammary carcinoma DX-PAA 18 > 15 >0.8
aDX, doxorubicin; DX-PAA, doxorubicin-poly-L-aspartic acid
conjugate; bdose providing a tumour growth inhibition _80% as
compared to untreated mice; CRatio between LDIo and effective dose.PAA AS A DOXORUBICIN CARRIER 847
of the anthracycline linked to PAA, in this
experimental model, is due to its phagocytic
properties (Talmadge et al., 1982), since apparently
free and polymer-linked drug displayed comparable
activity against the macrophage tumour J774.
However, it should be noted that in two separate
experiments (Table IV), the efficacy of free doxo-
rubicin in increasing survival time was markedly
different, in contrast to the reproducible effect of the
polymeric derivative. Thus, no definitive conclusions
could be drawn from these experiments. Relevant to
this point is the observation that in a variety of
experimental models, reproducible results were
generally obtained using different preparations of
the conjugate. This also reflects the stability of the
conjugate in aqueous solutions.
Taken together with previous results showing an
enhanced efficacy of the polymeric derivative as
compared to free doxorubicin against leukaemia
models (Zunino et al., 1984), the data presented
here suggest a therapeutic advantage of the drug
linked to PAA in tumours of tissues of
mesenchymal origin. Anyway, the attachment of
doxorubicin to this macromolecular carrier did not
cause loss or reduction of anti-tumour efficacy at
optimal doses in any of the tumour models used.
However, this means of drug delivery is not
expected to overcome drug resistance, since free
and polymer-linked doxorubicin produced a
marginal response against colon carcinoma 26 (not
shown), a tumour model, which, when growing
subcutaneously, is relatively resistant to anthra-
cycline therapy (Casazza et al., 1983). This is in
agreement with the absence of appreciable activity
of the conjugate against a doxorubicin-resistant
subline of P388 leukaemia (Zunino et al., 1982).
Finally, it remains to be clarified whether the
PAA conjugate has further therapeutic advantage
over free drug, when administered in an optimal
schedule. It should be noted that in all experiments
only optimal schedules of free drug were employed.
In conclusion, among the favourable properties
found for the doxorubicin-PAA conjugate in this
and previous studies, the following are of particular
interest: (i) reduced severity of some specific toxic
effects; (ii) increased effectiveness against all of the
leukaemia and sarcoma models tested; (iii) anti-
tumour activity fully retained in other experimental
tumour systems and (iv) improvement of the
therapeutic index, more evident in the treatment
of highly sensitive tumours (Gross leukaemia
[Zunino et al., 1984] and M5 reticulum cell sarcoma
[Table VI]).
Further studies on the preclinical toxicity of this
polymeric derivative are needed to fully evaluate
the therapeutic potential of this drug delivery
system.
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